Validation
Gene Symbol |
Curated Descriptions | Cell Lines | Isolations | Validations | Control-case | Tumor Stage & Subtype | Clinical Use | PMID |
|---|---|---|---|---|---|---|---|---|
| hsa-miR-222 | Hsa-miR-222 contributes to tumorigenicity of BCa cells through down-regulation of PDLIM2 and consequently activating NF-κB | MDA-MB-231 | Exoquick Exosome Isolation Kit | transmission electron microscopy | metastasis | 29778754 | ||
| hsa-miR-222 | Hsa-miR-222-rich D/exo could alter PTEN expression in acquired cells that may spread resistance capacity | MCF7 | ultracentrifugation | transmission electron microscopy | drug resistance | 24740415 | ||
| hsa-miR-223 | MiR-223 promoted the invasion of breast cancer cells via the Mef2c-β-catenin pathway | MDA-MB-231 | ultracentrifugation | electronic microscopy | 21939504 | |||
| hsa-miR-223-3p | Exosomal miR-223-3p may be a useful preoperative biomarker to identify the invasive lesions of DCIS patients diagnosed by biopsy | MCF7 | ultracentrifugation | electron microscope | 175 breast cancer patients (case) 3 healthy controls (control) | ductal carcinoma in?situ (DCIS) breast cancer? | early diagnosis | 29805680 |
| hsa-miR-27a | Hsa-miR-27a has significantly up-regulated and has been extensively implicated in cancer progression | MCF7,MDA-MB-2314T1 | ultracentrifugation | transmission electron microscopy | 11 breast cancer samples (case) 8 healthy samples (control) | triple negative metastatic breast carcinoma | 25446899 | |
| hsa-miR-29b-3p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-301a | MCF-Exo contains a higher amount of hsa-miR-301a,and overexpression has been considered a negative prognostic indicator in lymph node-negative (LNN) invasive ductal breast cancer | MCF7,MDA-MB231 | ultracentrifugation | electron microscopy | metastasis | 24468161 | ||
| hsa-miR-30a | Target gene prediction and pathway analysis showed the involvement of miR-100, miR-222, and miR-30a in pathways implicated in cancer pathogenesis, membrane vesiculation and therapy failure，the transmition of chemoresistance by a horizontal transfer of miRNAs | MCF7 | ultracentrifugation | transmission electron microscopy | drug resistance | 24740415 | ||
| hsa-miR-31 | Hsa-miR-31 modulates MCF-7 cells growth by specially targeting the histone deacetylase 2 | MCF7 | centrifugation | transmission electron microscopy | 30916359 | |||
| hsa-miR-328 | MDA-Exo also contains significant amounts of hsa-miR-328,which has been shown to target CD44,reduce cell adhesion,enhance cell migration and regulate capillary structure formation | MCF7,MDA-MB231 | ultracentrifugation | electron microscopy | metastasis | 24468161 |